Celiac disease: a comprehensive current review

Giacomo Caio, Umberto Volta, Anna Sapone, Daniel A Leffler, Roberto De Giorgio, Carlo Catassi, Alessio Fasano, Giacomo Caio, Umberto Volta, Anna Sapone, Daniel A Leffler, Roberto De Giorgio, Carlo Catassi, Alessio Fasano

Abstract

Background: Celiac disease remains a challenging condition because of a steady increase in knowledge tackling its pathophysiology, diagnosis, management, and possible therapeutic options.

Main body: A major milestone in the history of celiac disease was the identification of tissue transglutaminase as the autoantigen, thereby confirming the autoimmune nature of this disorder. A genetic background (HLA-DQ2/DQ8 positivity and non-HLA genes) is a mandatory determinant of the development of the disease, which occurs with the contribution of environmental factors (e.g., viral infections and dysbiosis of gut microbiota). Its prevalence in the general population is of approximately 1%, with female predominance. The disease can occur at any age, with a variety of symptoms/manifestations. This multifaceted clinical presentation leads to several phenotypes, i.e., gastrointestinal, extraintestinal, subclinical, potential, seronegative, non-responsive, and refractory. Although small intestinal biopsy remains the diagnostic 'gold standard', highly sensitive and specific serological tests, such as tissue transglutaminase, endomysial and deamidated gliadin peptide antibodies, have become gradually more important in the diagnostic work-up of celiac disease. Currently, the only treatment for celiac disease is a life-long, strict gluten-free diet leading to improvement in quality of life, ameliorating symptoms, and preventing the occurrence of refractory celiac disease, ulcerative jejunoileitis, and small intestinal adenocarcinoma and lymphoma.

Conclusions: The present review is timely and provides a thorough appraisal of various aspects characterizing celiac disease. Remaining challenges include obtaining a better understanding of still-unclear phenotypes such as slow-responsive, potential (minimal lesions) and seronegative celiac disease. The identification of alternative or complementary treatments to the gluten-free diet brings hope for patients unavoidably burdened by diet restrictions.

Keywords: Alternative treatment; Clinical phenotypes; Epidemiology; Genetics; Gluten-free diet; Histopathological findings; Pathogenesis; Serological markers.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Celiac disease pathogenesis. Partially digested gliadin fragments interact with chemokine receptor 3 on the apical side of epithelium (1) inducing a myeloid differentiation primary response 88-dependent release of zonulin (2). Zonulin interacts with the intestinal epithelium and triggers increased intestinal permeability (3). Functional loss of the gut barrier facilitates gliadin peptide translocation from lumen to the lamina propria (4). Gliadin peptides trigger release of IL-15, keratinocyte growth factor, and IL-8 (5), with consequent recruitment of neutrophils in the lamina propria (6). Simultaneously, alpha-amylase/trypsin inhibitors engage the Toll like receptor 4–MD2–CD14 complex with subsequent up-regulation of maturation markers and release of proinflammatory cytokines (7). Following innate immune-mediated apoptosis of intestinal cells with subsequent release of intracellular tissue transglutaminase, gliadin peptides are partially deamidated (8). Deamidated gliadin is recognized by DQ2/8+ antigen presenting cells (9) and then presented to T helper cells (10). T helper cells trigger activation and maturation of B cells, producing IgM, IgG, and IgA antibodies against tissue transglutaminase (11). T helper cells also produce pro-inflammatory cytokines (interferon γ and tumor necrosis factor α) (12), which in turn further increase gut permeability and, together with T killer cells, initiate the enteropathy. Damaged enterocytes express CD71 transporter also on their apical side, resulting in retrotranscytosis of secretory IgA-gliadin complexes (13), thus potentiating gluten trafficking from gut lumen to lamina propria. Ultimately, the interaction between CD4+ T cells in the lamina propria with gliadin induces their activation and proliferation, with production of proinflammatory cytokines, metalloproteases, and keratinocyte growth factor by stromal cells, which induces crypt hyperplasia and villous blunting secondary to intestinal epithelial cell death induced by intraepithelial lymphocytes. The hyperplastic crypts (14) are characterized by an expansion of the immature progenitor cells compartment (WNT) and downregulation of the Hedgehog signaling cascade. An increased number of stromal cells known to be part of the intestinal stem cell niche and increased levels of bone morphogenetic protein antagonists, like Gremlin-1 and Gremlin-2, may further contribute to the crypt hyperplasia present in celiac disease
Fig. 2
Fig. 2
Prevalence of clinical phenotypes of adult celiac disease in our experience
Fig. 3
Fig. 3
Causes of ongoing signs and/or symptoms of celiac disease (CD) despite a gluten-free diet (formerly referred to as ‘non-responsive’ CD). In this review, two clinical phenotypes have been proposed – ongoing active celiac disease (OACD), related to three main causes, and associated celiac disease conditions (ACDC), encompassing a wide array of diseases
Fig. 4
Fig. 4
Diagnostic algorithm for celiac disease diagnosis
Fig. 5
Fig. 5
Comparison between the two classifications for the duodenal biopsy
Fig. 6
Fig. 6
Diagnostic algorithm for seronegative villous atrophy. SIBO small intestinal bacterial overgrowth

References

    1. Fasano A, Catassi C. Celiac disease. N Engl J Med. 2012;367:2419–2426. doi: 10.1056/NEJMcp1113994.
    1. Volta U, Caio G, Stanghellini V, De Giorgio R. The changing clinical profile of celiac disease: a 15-year experience (1998-2012) in an Italian referral center. BMC Gastroenterol. 2014;14:194. doi: 10.1186/s12876-014-0194-x.
    1. Volta U, Caio G, Tovoli F, De Giorgio R. Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness. Cell Mol Immunol. 2013;10:383–392. doi: 10.1038/cmi.2013.28.
    1. de Lorgeril M, Salen P. Gluten and wheat intolerance today: are modern wheat strains involved? Int J Food Sci Nutr. 2014;65:577–581. doi: 10.3109/09637486.2014.886185.
    1. van den Broeck HC, de Jong HC, Salentijn EM, et al. Presence of celiac disease epitopes in modern and old hexaploid wheat varieties: wheat breeding may have contributed to increased prevalence of celiac disease. Theor Appl Genet. 2010;121:1527–1539. doi: 10.1007/s00122-010-1408-4.
    1. Bach JF. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol. 2018;18:105–120. doi: 10.1038/nri.2017.111.
    1. Corazza GR, Andreani ML, Biagi F, et al. The smaller size of the ‘coeliac iceberg’ in adults. Scand J Gastroenterol. 1997;32:917–919. doi: 10.3109/00365529709011202.
    1. Ivarsson A, Persson LA, Juto P, et al. High prevalence of undiagnosed coeliac disease in adults: a Swedish population-based study. J Intern Med. 1999;245:63–68. doi: 10.1046/j.1365-2796.1999.00403.x.
    1. Riestra S, Fernandez E, Rodrigo L, et al. Prevalence of coeliac disease in the general population of northern Spain. Scand J Gastroenterol. 2000;35:398–402. doi: 10.1080/003655200750023967.
    1. Volta U, Bellentani S, Bianchi FB, et al. High prevalence of celiac disease in Italian general population. Dig Dis Sci. 2001;46:1500–1505. doi: 10.1023/A:1010648122797.
    1. Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med. 2010;42:587–595. doi: 10.3109/07853890.2010.505931.
    1. Rubio-Tapia A, Ludvigsson JF, Brantner TL, et al. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012;107:1538–1544. doi: 10.1038/ajg.2012.219.
    1. Singh P, Arora S, Singh A, et al. Prevalence of celiac disease in Asia: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;3:1095–1101. doi: 10.1111/jgh.13270.
    1. Catassi C, Kryszak D, Bhatti B, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42:530–538. doi: 10.3109/07853890.2010.514285.
    1. Hall EJ, Batt RM. Dietary modulation of gluten sensitivity in a naturally occurring enteropathy of Irish setter dogs. Gut. 1992;33:198–205. doi: 10.1136/gut.33.2.198.
    1. Okada H, Kuhn C, Feillet H, Bach J. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol. 2010;160:1-9.
    1. Verdu EF, Galipeau HJ, Jabri B. Novel players in celiac disease pathogenesis: the role of gut microbiota. Nat Rev Gastroenterol Hepatol. 2015;185:2969–2982.
    1. Lundin KE, Wijmenga C. Coeliac disease and autoimmune disease-genetic overlap and screening. Nat Rev Gastroenterol Hepatol. 2015;12:507–515. doi: 10.1038/nrgastro.2015.136.
    1. Lionetti E, Castellaneta S, Francavilla R, et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. N Engl J Med. 2014;371:1295–1303. doi: 10.1056/NEJMoa1400697.
    1. Liu E, Lee HS, Aronsson CA, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med. 2014;371:42–49. doi: 10.1056/NEJMoa1313977.
    1. Vriezinga SL, Auricchio R, Bravi E, et al. Randomized feeding intervention in infants at high risk for celiac disease. N Engl J Med. 2014;371:1304–1315. doi: 10.1056/NEJMoa1404172.
    1. Mazzilli MC, Ferrante P, Mariani P, et al. A study of Italian pediatric celiac disease patients confirms that the primary HLA association is to the DQ (α1∗ 0501, β1∗ 0201) heterodimer. Human Immunol. 1992;33:133–139. doi: 10.1016/0198-8859(92)90064-T.
    1. Dieli-Crimi R, Cénit MC, Núñez C. The genetics of celiac disease: a comprehensive review of clinical implications. J Autoimmun. 2015;64:26–41. doi: 10.1016/j.jaut.2015.07.003.
    1. Silano M, Vincentini O, De Vincenzi M. Toxic, immunostimulatory and antagonist gluten peptides in celiac disease. Curr Med Chem. 2009;16:1489–1498. doi: 10.2174/092986709787909613.
    1. Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297:2275–2279. doi: 10.1126/science.1074129.
    1. Jelinkova L, Tuckova L, Cinova J, et al. Gliadin stimulates human monocytes to production of IL-8 and TNF-alpha through a mechanism involving NF-kappaB. FEBS Lett. 2004;571:81–85. doi: 10.1016/j.febslet.2004.06.057.
    1. Lammers KM, Khandelwal S, Chaudhry F, et al. Identification of a novel immunomodulatory gliadin peptide that causes interleukin-8 release in a chemokine receptor CXCR3-dependent manner only in patients with coeliac disease. Immunology. 2011;132:432–440. doi: 10.1111/j.1365-2567.2010.03378.x.
    1. Picarelli A, Di Tola M, Sabbatella L, et al. 31–43 amino acid sequence of the alpha-gliadin induces anti-endomysial antibody production during in vitro challenge. Scand J Gastroenterol. 1999;34:1099–1102. doi: 10.1080/003655299750024896.
    1. Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut. 2003;52:218–223. doi: 10.1136/gut.52.2.218.
    1. Sander GR, Cummins AG, Henshall T, Powell BC. Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett. 2005;579:4851–4855. doi: 10.1016/j.febslet.2005.07.066.
    1. Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci. 2000;113:4435–4440.
    1. Fasano A, Not T, Wang W, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet. 2000;355:1518–1519. doi: 10.1016/S0140-6736(00)02169-3.
    1. Tripathi A, Lammers KM, Goldblum S, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A. 2009;106:16799–16804. doi: 10.1073/pnas.0906773106.
    1. El Asmar R, Panigrahi P, Bamford P, et al. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology. 2002;123:1607–1615. doi: 10.1053/gast.2002.36578.
    1. Smecuol E, Sugai E, Niveloni S, et al. Permeability, zonulin production, and enteropathy in dermatitis herpetiformis. Clin Gastroenterol Hepatol. 2005;3:335–341. doi: 10.1016/S1542-3565(04)00778-5.
    1. Sapone A, de Magistris L, Pietzak M, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes. 2006;55:1443–1449. doi: 10.2337/db05-1593.
    1. Simpson M, Mojibian M, Barriga K, et al. An exploration of Glo-3A antibody levels in children at increased risk for type 1 diabetes mellitus. Pediatr Diabetes. 2009;10:563–572. doi: 10.1111/j.1399-5448.2009.00541.x.
    1. Duerksen DR, Wilhelm-Boyles C, Veitch R, et al. A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet. Dig Dis Sci. 2010;55:1026–1031. doi: 10.1007/s10620-009-0813-5.
    1. Drago S, El Asmar R, Di Pierro M, et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. 2006;41:408–419. doi: 10.1080/00365520500235334.
    1. Hollon J, Puppa EL, Greenwald B, et al. Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity. Nutrients. 2015;7:1565–1576. doi: 10.3390/nu7031565.
    1. Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007;26:757–766. doi: 10.1111/j.1365-2036.2007.03413.x.
    1. Thomas KE, Sapone A, Fasano A, Vogel SN. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in celiac disease. J Immunol. 2006;176:2512–2521. doi: 10.4049/jimmunol.176.4.2512.
    1. Lammers KM, Lu R, Brownley J, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008;135:194–204. doi: 10.1053/j.gastro.2008.03.023.
    1. Monsuur AJ, de Bakker PI, Alizadeh BZ, et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet. 2005;37:1341–1344. doi: 10.1038/ng1680.
    1. Loeff T, Araya M, Pérez-Bravo F. Frequency of MYO9B polymorphisms in celiac patients and controls. Rev Esp Enferm Dig. 2012;104:566–571. doi: 10.4321/S1130-01082012001100003.
    1. Wapenaar MC, Monsuur AJ, van Bodegraven AA, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut. 2008;57:463–467. doi: 10.1136/gut.2007.133132.
    1. Schumann M, Richter JF, Wedell I, et al. Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut. 2008;57:747–754. doi: 10.1136/gut.2007.136366.
    1. Moreno ML, Cebolla Á, Muñoz-Suano A, et al. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. Gut. 2017;66:250–257. doi: 10.1136/gutjnl-2015-310148.
    1. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med. 2008;205:143–154. doi: 10.1084/jem.20071204.
    1. Kim SM, Mayassi T, Jabri B. Innate immunity: actuating the gears of celiac disease pathogenesis. Best Pract Res Clin Gastroenterol. 2015;29:425–435. doi: 10.1016/j.bpg.2015.05.001.
    1. Junker Y, Zeissig S, Kim SJ, et al. Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med. 2012;209:2395–2408. doi: 10.1084/jem.20102660.
    1. Barone MV, Troncone R, Auricchio S. Gliadin peptides as triggers of the proliferative and stress/innate immune response of the celiac small intestinal mucosa. Int J Mol Sci. 2014;15:20518–20537. doi: 10.3390/ijms151120518.
    1. Cinova J, Palova-Jelinkova L, Smythies LE, et al. Gliadin peptides activate blood monocytes from patients with celiac disease. J Clin Immunol. 2007;27:201–209. doi: 10.1007/s10875-006-9061-z.
    1. Lammers KM, Chieppa M, Liu L, et al. Gliadin induces neutrophil migration via engagement of the formyl peptide receptor, FPR1. PLoS One. 2015;10:e0138338. doi: 10.1371/journal.pone.0138338.
    1. Stamnaes J, Sollid LM. Celiac disease: autoimmunity in response to food antigen. Semin Immunol. 2015;27:343–352. doi: 10.1016/j.smim.2015.11.001.
    1. Tang F, Chen Z, Ciszewski C, et al. Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. J Exp Med. 2009;206:707–719. doi: 10.1084/jem.20071887.
    1. Tjon JM, van Bergen J, Koning F. Celiac disease: how complicated can it get? Immunogenetics. 2010;62:641–651. doi: 10.1007/s00251-010-0465-9.
    1. Pagliari D, Urgesi R, Frosali S, et al. The interaction among microbiota, immunity, and genetic and dietary factors is the condicio sine qua non celiac disease can develop. J Immunol Res. 2015;2015:123653.
    1. Hüe S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity. 2004;21:367–377. doi: 10.1016/j.immuni.2004.06.018.
    1. Senger S, Sapone A, Fiorentino MR, et al. Celiac disease histopathology recapitulates hedgehog downregulation, consistent with wound healing processes activation. PLoS One. 2015;10:e0144634. doi: 10.1371/journal.pone.0144634.
    1. Ju JM, Marietta EV, Murray JA. Generating transgenic mouse models for studying celiac disease. Methods Mol Biol. 2015;1326:23–33. doi: 10.1007/978-1-4939-2839-2_3.
    1. Schumann M, Siegmund B, Schulzke JD, Fromm M. Celiac disease: role of the epithelial barrier. Cell Mol Gastroenterol Hepatol. 2017;3:150–162. doi: 10.1016/j.jcmgh.2016.12.006.
    1. Olivares M, Benítez-Páez A, de Palma G, et al. Increased prevalence of pathogenic bacteria in the gut microbiota of infants at risk of developing celiac disease: the PROFICEL study. Gut Microbes. 2018;9:551–558.
    1. Chander AM, Yadav H, Jain S, et al. Cross-talk between gluten, intestinal microbiota and intestinal mucosa in celiac disease: recent advances and basis of autoimmunity. Front Microbiol. 2018;9:2597. doi: 10.3389/fmicb.2018.02597.
    1. Sellitto M, Bai G, Serena G, et al. Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. PLoS One. 2012;7:e33387. doi: 10.1371/journal.pone.0033387.
    1. Olivares M, Neef A, Castillejo G, et al. The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. Gut. 2015;64:406–417. doi: 10.1136/gutjnl-2014-306931.
    1. Choung RS, Ditah IC, Nadeau AM, et al. Trends and racial/ethnic disparities in gluten-sensitive problems in the United States: findings from the National Health and nutrition examination surveys from 1988 to 2012. Am J Gastroenterol. 2015;110:455–461. doi: 10.1038/ajg.2015.8.
    1. Fasano A. Celiac disease: how to handle a clinical chamaleon. N Engl J Med. 2003;348:2568–2570. doi: 10.1056/NEJMe030050.
    1. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;6:43–52. doi: 10.1136/gutjnl-2011-301346.
    1. Leonard MM, Sapone A, Catassi C, Fasano A. Celiac disease and nonceliac gluten sensitivity: a review. JAMA. 2017;318:647–656. doi: 10.1001/jama.2017.9730.
    1. Vivas S, Ruiz de Morales JM, Fernandez M, et al. Age-related clinical, serological, and histopathological features of celiac disease. Am J Gastroenterol. 2008;103:2360–2365. doi: 10.1111/j.1572-0241.2008.01977.x.
    1. Reilly NR, Aguilar K, Hassid BG, et al. Celiac disease in normal-weight and overweight children: clinical features and growth outcomes following a gluten-free diet. J Pediatr Gastroenterol Nutr. 2011;53:528–531.
    1. Baydoun A, Maakaron JE, Halawi H, et al. Hematological manifestations of celiac disease. Scand J Gastroenterol. 2012;47:1401–1411. doi: 10.3109/00365521.2012.706828.
    1. Kamycheva E, Goto T, Camargo CA., Jr Celiac disease is associated with reduced bone mineral density and increased FRAX scores in the US National Health and nutrition examination survey. Osteoporos Int. 2017;28:781–790. doi: 10.1007/s00198-016-3791-4.
    1. Krzywicka B, Herman K, Kowalczyk-Zając M, Pytrus T. Celiac disease and its impact on the oral health status – review of the literature. Adv Clin Exp Med. 2014;23:675–681. doi: 10.17219/acem/37212.
    1. Volta U, De Franceschi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet. 1998;352:26–29. doi: 10.1016/S0140-6736(97)11222-3.
    1. Volta U, Caio G, Tovoli F, De Giorgio R. Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Rev Gastroenterol Hepatol. 2013;7:253–261. doi: 10.1586/egh.13.5.
    1. Volta U, Tovoli F, Caio G. Clinical and immunological features of celiac disease in patients with type 1 diabetes mellitus. Expert Rev Gastroenterol Hepatol. 2011;5:479–487. doi: 10.1586/egh.11.38.
    1. Caio G, De Giorgio R, Venturi A, et al. Clinical and immunological relevance of anti-neuronal antibodies in celiac disease with neurological manifestations. Gastroenterol Hepatol Bed Bench. 2015;8:146–152.
    1. Saccone G, Berghella V, Sarno L, et al. Celiac disease and obstetric complications: a systematic review and metanalysis. Am J Obstet Gynecol. 2016;214:225–234. doi: 10.1016/j.ajog.2015.09.080.
    1. Farthing MJG, Edwards CRW, Rees LH, Dawson AM. Male gonadal function in coeliac disease: sexual dysfunction, infertility and semen quality. Gut. 1982;23:608–614. doi: 10.1136/gut.23.7.608.
    1. Leffler DA, Green PH, Fasano A. Extraintestinal manifestations of coeliac disease. Nat Rev Gastroenterol Hepatol. 2015;12:561–571. doi: 10.1038/nrgastro.2015.131.
    1. Gale L, Wimalaratna H, Brotodiharjo A, Duggan JM. Down’s syndrome is strongly associated with coeliac disease. Gut. 1997;40:492–496. doi: 10.1136/gut.40.4.492.
    1. Bonamico M, Pasquino AM, Mariani P, et al. Prevalence and clinical picture of celiac disease in turner syndrome. J Clin Endocrinol Metab. 2002;87:5495–5498. doi: 10.1210/jc.2002-020855.
    1. Giannotti A, Tiberio G, Castro M, et al. Coeliac disease in Williams syndrome. J Med Genet. 2001;38:767–768. doi: 10.1136/jmg.38.11.767.
    1. Caio G, De Giorgio R, Ursini F, et al. Prevalence of celiac disease serological markers in a cohort of Italian rheumatological patients. Gastroenterol Hepatol Bed Bench. 2018;11:244–249.
    1. Volta U, De Franceschi L, Molinaro N, et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci. 1998;43:2190–2195. doi: 10.1023/A:1026650118759.
    1. Volta U, Rodrigo L, Granito A, et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol. 2002;97:2609–2613. doi: 10.1111/j.1572-0241.2002.06031.x.
    1. Volta U, Bardazzi F, Zauli D, et al. Serological screening for coeliac disease in vitiligo and alopecia areata. Br J Dermatol. 1997;136:801–802. doi: 10.1111/j.1365-2133.1997.tb03684.x.
    1. Oleary C, Walsh CH, Wieneke P, et al. Coeliac disease and autoimmune Addison’s disease: a clinical pitfall. QJM. 2002;95:79–82. doi: 10.1093/qjmed/95.2.79.
    1. Cataldo F, Marino V, Ventura A, et al. Prevalence and clinical features of selective immunoglobulin a deficiency in coeliac disease: an Italian multicentre study. Gut. 1998;42:362–365. doi: 10.1136/gut.42.3.362.
    1. Curione M, Barbato M, De Biase L, et al. Prevalence of coeliac disease in idiopathic dilated cardiomiopathy. Lancet. 1999;354:222–223. doi: 10.1016/S0140-6736(99)01501-9.
    1. Caio G, De Giorgio R, Volta U. Coeliac disease and dermatitis herpetiformis. Lancet. 2018;392:916–917. doi: 10.1016/S0140-6736(18)31486-7.
    1. Volta U, Caio G, Boschetti E, et al. Seronegative celiac disease: shedding light on an obscure clinical entity. Dig Liver Dis. 2016;48:1018–1022. doi: 10.1016/j.dld.2016.05.024.
    1. Mooney PD, Evans KE, Singh S, Sanders DS. Treatment failure in coeliac disease: a practical guide to investigation and treatment of non-responsive and refractory coeliac disease. J Gastrointest Liver Dis. 2012;21:197–203.
    1. Volta U, Granito A, Fiorini E, et al. Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up. Dig Dis Sci. 2008;853:1582–1588. doi: 10.1007/s10620-007-0058-0.
    1. Volta U, Tovoli F, Piscaglia M, et al. Old and new serological test for celiac disease screening. Exp Rev Gatroenterol Hepatol. 2010;4:31–35. doi: 10.1586/egh.09.66.
    1. Caio G, Volta U. Coeliac disease: changing diagnostic criteria? Gastroenterol Hepatol Bed Bench. 2012;5:119–122.
    1. Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136–160. doi: 10.1097/MPG.0b013e31821a23d0.
    1. Werkstetter KJ, Korponay-Szabó IR, Popp A, et al. Accuracy in diagnosis of celiac disease without biopsies in clinical practice. Gastroenterology. 2017;153:924–935. doi: 10.1053/j.gastro.2017.06.002.
    1. Egner W, Shrimpton A, Sargur R, et al. ESPGHAN guidance on coeliac disease 2012: multiples of ULN for decision making do not harmonise assay performance across centres. J Pediatr Gastroenterol Nutr. 2012;55:733–735. doi: 10.1097/MPG.0b013e31826531f6.
    1. Fuchs V, Kurppa K, Huhtala H, et al. Serology-based criteria for adult coeliac disease have excellent accuracy across the range of pre-test probabilities. Aliment Pharmacol Ther. 2019;49:277–284. doi: 10.1111/apt.15109.
    1. Catassi C, Fasano A. Celiac disease diagnosis: simple rules are better than complicated algorithms. Am J Med. 2010;123:691–693. doi: 10.1016/j.amjmed.2010.02.019.
    1. Kostopoulou O, Devereaux-Walsh C, Delaney BC. Missing celiac disease in family medicine: the importance of hypothesis generation. Med Decis Mak. 2009;29:282–290. doi: 10.1177/0272989X08327493.
    1. Zanchetta MB, Longobardi V, Bai JC. Bone and celiac disease. Curr Osteoporos Rep. 2016;14:43–48. doi: 10.1007/s11914-016-0304-5.
    1. Corazza GR, Zoli G, Di Sabatino A, et al. A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol. 1999;94:391–397. doi: 10.1111/j.1572-0241.1999.00865.x.
    1. Caraceni P, Benazzi B, Caio G, et al. Hyposplenism as a cause of pneumococcal meningoencephalitis in an adult patient with celiac disease. Ital J Med. 2011;5:124–127. doi: 10.1016/j.itjm.2011.02.005.
    1. Di Sabatino A, Rosado MM, Cazzola P, et al. Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol. 2006;4:179–186. doi: 10.1016/S1542-3565(05)00982-1.
    1. Caio G, Riegler G, Patturelli M, et al. Pathophysiology of non-celiac gluten sensitivity: where are we now? Minerva Gastroenterol Dietol. 2017;63:16–21.
    1. Villalta D, Tonutti E, Prause C, et al. IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA deficiency. Clin Chem. 2010;56:464–468. doi: 10.1373/clinchem.2009.128132.
    1. Volta U, Molinaro N, De Franceschi L, et al. IgA anti-endomysial antibodies on human umbilical cord tissue for celiac disease screening: save both money and monkeys. Dig Dis Sci. 1995;40:1902–1905. doi: 10.1007/BF02208653.
    1. Stern M. Comparative evaluation of serologic tests for celiac disease: a European initiative toward standardization. J Pediatr Gastroenterol Nutr. 2000;31:513–519. doi: 10.1097/00005176-200011000-00012.
    1. Salardi S, Volta U, Zucchini S, et al. Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990s: an 18-year longitudinal study based on anti-endomysial antibodies. J Pediatr Gastroenterol Nutr. 2008;46:612–614. doi: 10.1097/MPG.0b013e31815d697e.
    1. Zucchini L, Giusti D, Gatouillat G, et al. Interpretation of serological tests in the diagnosis of celiac disease: anti-deamidated gliadin peptide antibodies revisited. Autoimmunity. 2016;49:414–420. doi: 10.1080/08916934.2016.1203908.
    1. Amarri S, Alvisi P, De Giorgio R, et al. Antibodies to deamidated gliadin peptides: an accurate predictor of coeliac disease in infancy. J Clin Immunol. 2013;33:1027–1030. doi: 10.1007/s10875-013-9888-z.
    1. Dipper CR, Maitra S, Thomas R, et al. Anti-tissue transglutaminase antibodies in the follow-up of adult coeliac disease. Aliment Parmacol Ther. 2009;30:236–244. doi: 10.1111/j.1365-2036.2009.04039.x.
    1. Choung RS, Khaleghi Rostamkolaei S, Ju JM, et al. Synthetic neoepitopes of the transglutaminase-deamidated gliadin complex as biomarkers for diagnosing and monitoring celiac disease. Gastroenterology. 2019;156:582–591. doi: 10.1053/j.gastro.2018.10.025.
    1. Leonard MM, Weir DC, DeGroote M, et al. Value of IgA tTG in predicting mucosal recovery in children with celiac disease on a gluten-free diet. J Pediatr Gastroenterol Nutr. 2017;64:286–291. doi: 10.1097/MPG.0000000000001460.
    1. Leonard MM, Fasano A. Zero, one, or two endoscopies to diagnose and monitor pediatric celiac disease? The jury is still out. J Pediatr Gastroenterol Nutr. 2017;65:270–271. doi: 10.1097/MPG.0000000000001666.
    1. Oberhüber G, Granditsch G, Vogelsang H. The histopathology of celiac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11:1185–1194. doi: 10.1097/00042737-199910000-00019.
    1. Corazza GR, Villanacci V. Coeliac disease: some considerations on the histological diagnosis. J Clin Pathol. 2005;58:573–574. doi: 10.1136/jcp.2004.023978.
    1. Oxentenko AS, Murray JA. Celiac disease: ten things that every gastroenterologist should know. Clin Gastroenterol Hepatol. 2015;13:1396–1404. doi: 10.1016/j.cgh.2014.07.024.
    1. Villanacci V, Ceppa P, Tavani E, et al. Coeliac disease: the histology report. Dig Liver Dis. 2011;43:385–395. doi: 10.1016/S1590-8658(11)60594-X.
    1. Rostami-Nejad M, Villanacci V, Hogg-Kollars S, et al. Endoscopic and histological pitfalls in the diagnosis of celiac disease: a multicentre study assessing the current practice. Rev Esp Enferm Dig. 2013;105:326–333. doi: 10.4321/S1130-01082013000600003.
    1. Brown I, Mino-Kenudson M, Deshpande V, Lauwers GY. Intraepithelial lymphocytosis in architecturally preserved proximal small intestinal mucosa. Arch Pathol Lab Med. 2006;130:1020–1025.
    1. Biagi F, Bianchi PI, Campanella J, et al. The prevalence and the causes of minimal intestinal lesions in patients complaining of symptoms suggestive of enteropathy. A follow-up study. J Clin Pathol. 2008;61:1116–1118. doi: 10.1136/jcp.2008.060145.
    1. Kakar S, Nehra V, Murray JA, et al. Significance of intraepithelial lymphocytosis in small bowel biopsy samples with normal mucosa architecture. Am J Gastroenterol. 2003;98:2027–2033. doi: 10.1111/j.1572-0241.2003.07631.x.
    1. Upton MP. “Give us this day our daily bread”. Evolving concepts in celiac sprue. Arch Pathol Lab Med. 2008;132:1594–1599.
    1. Fernández-Bañares F, Carrasco A, García-Puig R, et al. Intestinal intraepithelial lymphocyte cytometric pattern is more accurate than subepithelial deposits of anti-tissue transglutaminase IgA for the diagnosis of celiac disease in lymphocytic enteritis. PLoS One. 2014;9:e101249. doi: 10.1371/journal.pone.0101249.
    1. Rostami K, Marsh MN, Johnson MW, et al. ROC-king onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation. Gut. 2017;66:2080–2086. doi: 10.1136/gutjnl-2017-314297.
    1. Marsh MN, Rostami K. What is a normal intestinal mucosa? Gastroenterology. 2016;151:784–788. doi: 10.1053/j.gastro.2016.09.030.
    1. Marsh MN, Johnson WM, Rostami K. Mucosal histopathology in celiac disease: a rebuttal of Oberhuber's sub-division of Marsh III. Gastroenterol Hepatol Bed Bench. 2015;8:99–109.
    1. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656–676. doi: 10.1038/ajg.2013.79.
    1. Volta U, Villanacci V. Celiac disease: diagnostic criteria in progress. Cell Mol Immunol. 2011;8:96–102. doi: 10.1038/cmi.2010.64.
    1. Volta U, Caio G, Giancola F, et al. Features and progression of potential celiac disease in adults. Clin Gastroenterol Hepatol. 2016;14:686–693. doi: 10.1016/j.cgh.2015.10.024.
    1. Kurppa K, Collin P, Viljamaa M, et al. Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. Gastroenterology. 2009;136:816–823. doi: 10.1053/j.gastro.2008.11.040.
    1. Tosco A, Salvati VM, Auricchio R, et al. Natural history of potential celiac disease in children. Clin Gastroenterol Hepatol. 2011;9:320–325. doi: 10.1016/j.cgh.2010.09.006.
    1. Lionetti E, Castellaneta S, Pulvirenti A, et al. Prevalence and natural history of potential celiac disease in at-family-risk infants prospectively investigated from birth. J Pediatr. 2012;161:908–914. doi: 10.1016/j.jpeds.2012.05.008.
    1. Zanini B, Caselani F, Magni A, et al. Celiac disease with mild enteropathy is not mild disease. Clin Gastroenterol Hepatol. 2013;11:253–258. doi: 10.1016/j.cgh.2012.09.027.
    1. Biagi F, Trotta L, Alfano C, et al. Prevalence and natural history of potential celiac disease in adult patients. Scand J Gastroenterol. 2013;48:537–542. doi: 10.3109/00365521.2013.777470.
    1. Auricchio R, Tosco A, Piccolo E, et al. Potential celiac children: 9-year follow-up on a gluten-containing diet. Am J Gastroenterol. 2014;109:913–921. doi: 10.1038/ajg.2014.77.
    1. Kurppa K, Collin P, Lindfors K, et al. Spontaneous negative seroconversion of endomysial antibodies does not exclude subsequent celiac disease. J Pediatr Gastroenterol Nutr. 2011;53:576–579. doi: 10.1097/MPG.0b013e31821c974f.
    1. Rostami K, Kerckhaert J, Tiemessen R, et al. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am J Gastroenterol. 1999;94:888–894. doi: 10.1111/j.1572-0241.1999.983_f.x.
    1. Shah VH, Rotterdam H, Kotler DP, et al. All that scallops is not celiac disease. Gastrointest Endosc. 2000;51:717–720. doi: 10.1067/mge.2000.104977.
    1. Greenson JK. The biopsy pathology of non-coeliac enteropathy. Histopathology. 2015;66:29–36. doi: 10.1111/his.12522.
    1. De Gaetani M, Tennyson CA, Lebwohl B, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108:647–653. doi: 10.1038/ajg.2013.45.
    1. Aziz I, Peerally MF, Barnes JH, et al. The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000-2015) Gut. 2017;66:1563–1572. doi: 10.1136/gutjnl-2016-312271.
    1. Dewar DH, Donnelly SC, McLaughlin SD, et al. Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J Gastroenterol. 2012;18:1348–1356. doi: 10.3748/wjg.v18.i12.1348.
    1. Rubio-Tapia A, Ludvigsson JF, Choung RS, et al. Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III. BMC Gastroenterol. 2016;16:136. doi: 10.1186/s12876-016-0547-8.
    1. Biagi F, Gobbi P, Marchese A, et al. Low incidence but poor prognosis of complicated coeliac disease: a retrospective multicentre study. Dig Liver Dis. 2014;46:227–230. doi: 10.1016/j.dld.2013.10.010.
    1. Al-Toma A, Goerres MS, Meijer JW, et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol. 2006;4:315–319. doi: 10.1016/j.cgh.2005.12.011.
    1. Di Sabatino A, Brunetti L, Carnevale Maffè G, et al. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol. 2013;19:2313–2318. doi: 10.3748/wjg.v19.i15.2313.
    1. Roshan B, Leffler DA, Jamma S, et al. The incidence and clinical spectrum of refractory celiac disease in a north American referral center. Am J Gastroenterol. 2011;106:923–928. doi: 10.1038/ajg.2011.104.
    1. Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009;136:81–90. doi: 10.1053/j.gastro.2008.09.069.
    1. Nasr Ikram, Nasr Iman, Campling Hannah, Ciclitira Paul J. Approach to patients with refractory coeliac disease. F1000Research. 2016;5:2544. doi: 10.12688/f1000research.9051.1.
    1. Nasr I, Nasr I, Beyers C, et al. Recognising and managing refractory coeliac disease: a tertiary Centre experience. Nutrients. 2015;7:9896–9907. doi: 10.3390/nu7125506.
    1. Williams MJ, Sutherland DH, Clark CG. Lymphosarcoma of the small intestine with a malabsorption syndrome and pneumatosis intestinalis. Report of a case with peroral jejunal biopsy. Gastroenterology. 1963;45:550e7. doi: 10.1016/S0016-5085(19)34852-8.
    1. Silano M, Volta U, Mecchia AM, et al. Delayed diagnosis of coeliac disease increases cancer risk. BMC Gastroenterol. 2007;7:8. doi: 10.1186/1471-230X-7-8.
    1. Malamut G, Cellier C. Complications of coeliac disease. Best Pract Res Clin Gastroenterol. 2015;29:451–458. doi: 10.1016/j.bpg.2015.05.005.
    1. Cheminant Morgane, Bruneau Julie, Malamut Georgia, Sibon David, Guegan Nicolas, van Gils Tom, Cording Sascha, Trinquand Amélie, Verkarre Virginie, Lhermitte Ludovic, Brousse Nicole, Jannot Anne-Sophie, Khater Sherine, Frenzel Laurent, Delarue Richard, Suarez Felipe, Marçais Ambroise, Mulder Chris JJ, Macintyre Elizabeth, Asnafi Vahid, Pouyet Laurent, Bonnafous Cécile, Lhospice Florence, Molina Thierry Jo, Meresse Bertrand, Cellier Christophe, Cerf-Bensussan Nadine, Hermine Olivier. NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. Gut. 2018;68(8):1396–1405. doi: 10.1136/gutjnl-2018-317371.
    1. Ilus T, Kaukinen K, Virta LJ, et al. Incidence of malignancies in diagnosed celiac patients: a population-based estimate. Am J Gastroenterol. 2014;109:1471–1477. doi: 10.1038/ajg.2014.194.
    1. Caio G, Volta U, Ursini F, et al. Small bowel adenocarcinoma as a complication of celiac disease: clinical and diagnostic features. BMC Gastroenterol. 2019;19:45. doi: 10.1186/s12876-019-0964-6.
    1. Catassi C, Copparoni R, Corazza GR, et al. Protocollo per la diagnosi ed il follow-up della malattia celiaca. Gazzetta Ufficiale della Repubblica Italiana, Serie Generale n.191 del 19/08/2015, pp. 148–58.
    1. Tortora R, Capone P, De Stefano G, et al. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. Aliment Pharmacol Ther. 2015;41:352–359. doi: 10.1111/apt.13062.
    1. Reilly NR, Lebwohl B, Hultcrantz R, et al. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. J Hepatol. 2015;62:1405–1411. doi: 10.1016/j.jhep.2015.01.013.
    1. Laurikka P, Salmi T, Collin P, et al. Gastrointestinal symptoms in celiac disease patients on a long-term gluten-free diet. Nutrients. 2016;14:8.
    1. Thompson T. Folate, iron, and dietary fiber contents of the gluten-free diet. J Am Diet Assoc. 2000;100:1389–1396. doi: 10.1016/S0002-8223(00)00386-2.
    1. Carroccio A, Ambrosiano G, Di Prima L, et al. Clinical symptoms in celiac patients on a gluten-free diet. Scand J Gastroenterol. 2008;43:1315–1321. doi: 10.1080/00365520802200044.
    1. Valitutti F, Trovato CM, Montuori M, Cucchiara S. Pediatric celiac disease: follow-up in the spotlight. Adv Nutr. 2017;8:356–361. doi: 10.3945/an.116.013292.
    1. Mubarak A, Oudshoorn JH, Kneepkens CM, et al. A child with refractory coeliac disease. J Pediatr Gastroenterol Nutr. 2011;53:216–218. doi: 10.1097/MPG.0b013e318214553a.
    1. West J, Logan RF, Card TR, et al. Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study. Aliment Pharmacol Ther. 2004;20:73–79. doi: 10.1111/j.1365-2036.2004.02008.x.
    1. Hallert C, Grant C, Grehn S, et al. Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years. Aliment Pharmacol Ther. 2002;16:1333–1339. doi: 10.1046/j.1365-2036.2002.01283.x.
    1. Midhagen G, Hallert C. High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol. 2003;98:2023–2026. doi: 10.1111/j.1572-0241.2003.07632.x.
    1. Roos S, Kärner A, Hallert C. Psychological well-being of adult coeliac patients treated for 10 years. Dig Liver Dis. 2006;38:177–180. doi: 10.1016/j.dld.2006.01.004.
    1. Aziz I, Evans KE, Papageorgiou V, Sanders DS. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J Gastrointestin Liver Dis. 2011;20:27–31.
    1. McCarville JL, Caminero A, Verdu EF. Pharmacological approaches in celiac disease. Curr Opin Pharmacol. 2015;25:7–12. doi: 10.1016/j.coph.2015.09.002.
    1. Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148:1311–1319. doi: 10.1053/j.gastro.2015.02.008.
    1. Lähdeaho ML, Kaukinen K, Laurila K, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014;146:1649–1658. doi: 10.1053/j.gastro.2014.02.031.
    1. Gottlieb K, Dawson J, Hussain F, Murray JA. Development of drugs for celiac disease: review of endpoints for phase 2 and 3 trials. Gastroenterol Rep. 2015;3:91–102. doi: 10.1093/gastro/gov006.
    1. Murray JA, Kelly CP, Green PHR, et al. No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. Gastroenterology. 2017;152:787–798. doi: 10.1053/j.gastro.2016.11.004.
    1. Anderson RP, Jabri B. Vaccine against autoimmune disease: antigen-specific immunotherapy. Curr Opin Immunol. 2013;25:410–417. doi: 10.1016/j.coi.2013.02.004.
    1. Lionetti E, Castellaneta S, Francavilla R, et al. Mode of delivery and risk of celiac disease: risk of celiac disease and age at gluten introduction cohort study. J Pediatr. 2017;184:81–86. doi: 10.1016/j.jpeds.2017.01.023.
    1. Koletzko S, Lee HS, Beyerlein A, et al. Cesarean section on the risk of celiac disease in the offspring: the teddy study. J Pediatr Gastroenterol Nutr. 2018;66:417–424. doi: 10.1097/MPG.0000000000001682.
    1. Dydensborg Sander S, Hansen AV, Størdal K, et al. Mode of delivery is not associated with celiac disease. Clin Epidemiol. 2018;10:323–332. doi: 10.2147/CLEP.S152168.
    1. Silvester JA, Leffler DA. Is autoimmunity infectious? The effect of gastrointestinal viral infections and vaccination on risk of celiac disease autoimmunity. Clin Gastroenterol Hepatol. 2017;15:703–705. doi: 10.1016/j.cgh.2016.12.014.
    1. Leonard MM, Camhi S, Huedo-Medina TD, Fasano A. Celiac disease genomic, environmental, microbiome, and Metabolomic (CDGEMM) study design: approach to the future of personalized prevention of celiac disease. Nutrients. 2015;7:9325–9336. doi: 10.3390/nu7115470.
    1. Hujoel IA, Van Dyke CT, Brantner T, et al. Natural history and clinical detection of undiagnosed coeliac disease in a north American community. Aliment Pharmacol Ther. 2018;47:1358–1366. doi: 10.1111/apt.14625.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera